Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/3/2026 | $32.00 | Overweight | Analyst |
| 3/3/2026 | $28.00 | Overweight | Morgan Stanley |
| 3/3/2026 | $36.00 | Outperform | Leerink Partners |
20-F - Agomab Therapeutics NV (0002020932) (Filer)
SCHEDULE 13G - Agomab Therapeutics NV (0002020932) (Subject)
S-8 - Agomab Therapeutics NV (0002020932) (Filer)
Morgan Stanley initiated coverage of AgomAb Therapeutics NV with a rating of Overweight and set a new price target of $28.00
Analyst initiated coverage of AgomAb Therapeutics NV with a rating of Overweight and set a new price target of $32.00
Leerink Partners initiated coverage of AgomAb Therapeutics NV with a rating of Outperform and set a new price target of $36.00
-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 -- -- Positive Interactions with U.S. Food and Drug Administration (FDA) on Design of Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease (FSCD) ---- On Track to Initiate Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in Idiopathic Pulmonary Fibrosis (IPF) with AGMB-447 in Second Half of 2026 ---- Topline Data from Open-Label Long-term Extension Study (OLE) Part of STENOVA Study with Ontunisertib in FSCD and from Phase 1b IPF Study Cohort with AGMB-447 Expected in Second Hal
Antwerp, Belgium, March 26, 2026 – Agomab Therapeutics NV (NASDAQ:AGMB) ("'Agomab'"), a clinical-stage biopharmaceutical company focused on fibrosis, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,577,230, covering the composition of matter of AGMB-447, to Agomab. AGMB-447 is the company's investigational inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1), currently in a Phase 1b study for the treatment of Idiopathic Pulmonary Fibrosis (IPF). This patent provides intellectual property (IP) protection for AGMB-447 in the U.S. through at least 2041, excluding any potential patent term extensions. "The issuance of th
ANTWERP, Belgium, February 9, 2026 (GLOBE NEWSWIRE) – Agomab Therapeutics NV (NASDAQ:AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need, today announced the closing of its previously announced initial public offering of 12,500,000 American Depositary Shares ("ADSs") representing 12,500,000 of its common shares, at a public offering price of $16.00 per ADS. The aggregate gross proceeds to Agomab from the offering were approximately $200.0 million, before deducting underwriting discounts and commissions an
3 - Agomab Therapeutics NV (0002020932) (Issuer)
3 - Agomab Therapeutics NV (0002020932) (Issuer)
3 - Agomab Therapeutics NV (0002020932) (Issuer)